Table 1.
Baseline characteristics.
| All patients | SII-low patients | SII-high patients | p | ||||
|---|---|---|---|---|---|---|---|
| n = 706 | (%) | n = 311 | (%) | n = 310 | (%) | ||
| Age-years, median (IQR) | 60 (53–67) | 60 (53–69) | 60 (53–70) | 0.710 | |||
| Sex | 0.317 | ||||||
| Male | 531 | 75.2 | 229 | 73.6 | 239 | 77.1 | |
| Female | 175 | 24.8 | 82 | 26.4 | 71 | 22.9 | |
| Histological Type | 0.196 | ||||||
| Clear Cell | 563 | 79.7 | 241 | 77.5 | 257 | 82.9 | |
| Non-clear Cell | 94 | 13.3 | 46 | 14.8 | 36 | 11.6 | |
| Missing | 49 | 6.9 | 24 | 7.7 | 17 | 5.5 | |
| Sarcomatoid Feature | 0.830 | ||||||
| Yes | 83 | 11.8 | 35 | 11.3 | 39 | 12.6 | |
| No | 407 | 57.6 | 182 | 58.5 | 192 | 61.9 | |
| Missing | 216 | 30.6 | 94 | 30.2 | 79 | 25.5 | |
| Fuhrman Grade | 0.076 | ||||||
| 1–2 | 124 | 17.6 | 63 | 20.3 | 43 | 13.9 | |
| 3–4 | 297 | 42.1 | 129 | 41.4 | 133 | 42.9 | |
| Missing | 285 | 40.4 | 119 | 38.3 | 134 | 43.2 | |
| Previous Nephrectomy | < 0.001 | ||||||
| Yes | 525 | 74.4 | 260 | 83.6 | 199 | 64.2 | |
| No | 177 | 25.1 | 50 | 16.1 | 110 | 35.5 | |
| Missing | 4 | 0.6 | 1 | 0.3 | 1 | 0.3 | |
| Systemic Treatment | < 0.001 | ||||||
| Sunitinib | 404 | 57.2 | 197 | 63.3 | 152 | 49.0 | |
| Pazopanib | 302 | 42.8 | 114 | 36.7 | 158 | 51.0 | |
| IMDC Risk | < 0.001 | ||||||
| Favorable | 116 | 16.4 | 83 | 26.7 | 33 | 10.6 | |
| Intermediate | 332 | 47.0 | 175 | 56.3 | 152 | 49.0 | |
| Poor | 128 | 18.1 | 25 | 8.0 | 98 | 31.6 | |
| Missing | 130 | 18.4 | 28 | 9.0 | 27 | 8.7 | |
| MSKCC Risk | < 0.001 | ||||||
| Favorable | 91 | 12.9 | 64 | 20.6 | 27 | 8.7 | |
| Intermediate | 279 | 39.5 | 148 | 47.6 | 128 | 41.3 | |
| High | 87 | 12.3 | 27 | 8.7 | 59 | 19.0 | |
| Missing | 249 | 35.3 | 72 | 23.2 | 96 | 31.0 | |
| Previous Cytokine Use | 0.032 | ||||||
| Yes | 334 | 47.3 | 152 | 48.9 | 125 | 40.3 | |
| No | 372 | 52.7 | 159 | 51.1 | 185 | 59.7 | |
| Metastatic Sites | |||||||
| Lung | 319 | 51.4 | 161 | 51.8 | 158 | 51.0 | 0.886 |
| Bone | 259 | 41.7 | 100 | 32.2 | 159 | 51.3 | < 0.001 |
| Liver | 92 | 14.8 | 42 | 13.5 | 50 | 16.1 | 0.252 |
| CNS | 58 | 9.3 | 18 | 5.8 | 40 | 12.9 | 0.026 |
| Performance Status | 0.002 | ||||||
| ECOG 0–1 | 515 | 72.9 | 243 | 78.1 | 207 | 66.8 | |
| ECOG 2–3-4 | 149 | 21.1 | 55 | 17.7 | 87 | 28.1 | |
| Missing | 42 | 5.9 | 13 | 4.2 | 16 | 5.2 | |
ECOG eastern cooperative oncology group, IMDC international metastatic renal cell carcinoma database consortium, IQR interquartile range, MSKCC memorial sloan kettering cancer center.
Significant values are in bold.